BridgeBio reports infigratinib Phase 3 data
BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.
Bhutan has transferred about 400 Bitcoin (CRYPTO:BTC), worth roughly US$30.62 million, to an unlabelled external address.
MoonPay has received an Electronic Money Institution licence from De Nederlandsche Bank, allowing it to issue euro-denominated stablecoins.
Canadian Phosphate (ASX:CP8) extended the mineralisation strike at its Wapiti Phosphate Project.
Hyperliquid has burned 15,350 HYPE (CRYPTO:HYPE) worth about $1.32 million through its automated burn system.
Robinhood Chain has recorded a record $6 million in daily fees as trading activity surged across its decentralised exchange ecosystem.
Visa has reported stablecoin settlement volume above a $20 billion annualised run rate, up more than 15 times year over year.
Osteopore (ASX:OSX) secured market access in Thailand for its complete line of orthopaedic products.
Qualcomm (NASDAQ:QCOM) announced a multi-generation partnership with Amazon Web Services to develop custom AI data center chips, expanding its role in artificial intelligence infrastructure.
AEVEX Corp. (NYSE:AVEX) completed its acquisition of BlackSea Technologies, adding unmanned surface and subsea vessel capabilities to its autonomous defense systems business.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy